17/07/2026
🩸 Transforming Immune Monitoring: Introducing the GlycoStrip Platform!
We are excited to share our latest research published in Trends in Biotechnology titled: "Point-of-care GlycoStrips detect serum and salivary antibodies to blood group antigens and pathogens."
Traditional anti-glycan antibody detection relies on complex, centralized laboratory instrumentation. To bridge this gap, our team developed GlycoStrip - a visual, multiplex analytical device containing printed neoglycoproteins, glycoproteins, and viral/bacterial proteins onto a single, accessible platform.
Key Highlights:
- Multiplexed Profiling: Enables rapid antibody profiling to multiple glycan and protein antigens simultaneously, without the need for sophisticated instrumentation.
- Noninvasive/Minimal Invasive Sampling: Successfully validated using both serum and saliva, paving the way for real-time immune health monitoring.
- Broad Versatility: Tested with blood group antigens (neo-glycoproteins), SARS-CoV-2 spike glycoproteins, and E. coli K-12 cells.
GlycoStrip has the potential to decentralize immune monitoring, making personalized medicine and disease management highly accessible for chronic disease patients and underserved populations.
A huge thank you to the co-authors Tianwei Jia, Kelsey Charon, Maxence Noel, Praveen Singh, PhD, Stephan von Gunten, John Roback, Jamie Heimburg-Molinaro, Sean Stowell, and Richard Cummings, to make this possible!
🔗 Read the full open-access paper here: https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(26)00278-7
We present the development of GlycoStrip, which is a multiplex anti-glycan antibody analysis platform. GlycoStrip incorporates neoglycoproteins and other materials directly printed on nitrocellulose sheets to enable the visualization of anti-glycan antibody repertoires in bodily fluids within minute...